In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Atritech closes $30mm round

Executive Summary

Medical device company Atritech raised $30mm through a late-stage venture round led by Thomas, McNerney & Partners. Split Rock Partners, Prism Ventures, Tullis-Dickerson, and Vector Group also participated in the financing. The company will use the funds to complete FDA review and then market launch of its Watchman closure device, designed to prevent stroke-causing blood clots from entering the circulatory system in patients with atrial fibrillation. The PROTECT AF clinical trials are comparing the device to warfarin drug treatment, the current standard of care.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies